Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Quality of vision with monofocal and multifocal IOLs

Poster Details

First Author: R.Potvin USA

Co Author(s):    K. Gundersen              

Abstract Details



Purpose:

To compare patient-reported quality of vision after binocular implantation of monofocal, or apodized diffractive multifocal, IOLs.

Setting:

Single ophthalmology clinic.

Methods:

Patients with different binocular IOLs implanted were recruited after surgery and had their visual acuity tested, and quality of vision evaluated, at a single diagnostic visit between 3 and 8 months after second-eye surgery. Lenses tested included an aspheric monofocal (AcrySof® IQ) and two apodized diffractive multifocal IOLs (AcrySof® IQ ReSTOR +3 and AcrySof® IQ ReSTOR +2.5) with slightly different design parameters. The ReSTOR +2.5 lens distributes a higher percentage of light to distance at all pupil sizes. The NEI near vision 6-question subset and the Quality of Vision test were administered and scored using Rasch analysis to compare lenses.

Results:

The NEI near vision subset was administered and no differences were reported by patients. This questionnaire asks about near vision with no reference to spectacle use, so results were not surprising. With regard to the Quality of Vision test, the Rasch scores were significantly higher in the monofocal group but not significantly different between the two multifocal IOLs.

Conclusions:

The data indicate that the ReSTOR +2.5 IOL provided improved intermediate and near vision relative to a monofocal IOL. Quality of vision was not significantly different between the multifocal IOLs, but patient self-selection for each lens type may have been a factor. Patients choosing the ReSTOR +2.5 lens chose it based on a willingness to have less spectacle independence than patients with the ReSTOR +3.0 IOL, but with a lower likelihood of visual disturbances.

Financial Disclosure:

NONE

Back to previous